Patents by Inventor Mark Steven Cragg

Mark Steven Cragg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunomodulatory antibodies
    Patent number: 11780929
    Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: October 10, 2023
    Assignee: Cancer Research Technology Limited
    Inventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
  • IMMUNOMODULATORY ANTIBODIES
    Publication number: 20220213207
    Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.
    Type: Application
    Filed: April 20, 2021
    Publication date: July 7, 2022
    Applicant: Cancer Research Technology Limited
    Inventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
  • IMMUNOMODULATORY ANTIBODIES
    Publication number: 20210317222
    Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.
    Type: Application
    Filed: April 20, 2021
    Publication date: October 14, 2021
    Applicant: Cancer Research Technology Limited
    Inventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
  • Immunomodulatory antibodies
    Patent number: 11001638
    Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: May 11, 2021
    Assignee: Cancer Research Technology Limited
    Inventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
  • IMMUNOMODULATORY ANTIBODIES
    Publication number: 20200017594
    Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.
    Type: Application
    Filed: November 4, 2016
    Publication date: January 16, 2020
    Applicant: Cancer Research Technology Limited
    Inventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
  • CANCER AND B-CELL RELATED DISEASE THERAPY
    Publication number: 20190169306
    Abstract: The disclosure relates to a method of treatment or prevention of B-cell related disease in a subject comprising the administration of a binding molecule capable of binding to a B-cell and promoting killing of the B-cell; and an immunostimulatory agent arranged to stimulate effector lymphocytes, such as NK and/or T cells. Additionally, an anti-CD27 binding agent for use in a combination therapy with an anti-CD20 binding agent for the treatment or prevention of B-cell related disease in a subject. The disclosure also relates to a method of treatment or prevention of cancer in a subject comprising the administration of a cancer-cell-depleting binding agent capable of binding to the cancer cell and promoting killing of the cancer cell; and an immunostimulatory agent arranged to stimulate NK and/or T-cell activation. Additionally, an anti-CD27 binding agent for use in a combination therapy with a cancer-cell-depleting binding agent for the treatment or prevention of cancer in a subject.
    Type: Application
    Filed: July 28, 2017
    Publication date: June 6, 2019
    Inventors: Martin John Glennie, Aymen Al-Shamkhani, Mark Steven Cragg, Sean Hua Lim
  • IMMUNOMODULATORY ANTIBODIES
    Publication number: 20180327504
    Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 15, 2018
    Applicant: Cancer Research Technology Limited
    Inventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby